Poolbeg Pharma Company Top Insiders

POLBF Stock  USD 0.04  0.00  0.00%   
Poolbeg Pharma employs about 7 people. The company is managed by 4 executives with a total tenure of roughly 17 years, averaging almost 4.0 years of service per executive, having 1.75 employees per reported executive. Examination of Poolbeg Pharma's management performance can provide insight into the company performance.
Jeremy Skillington  Insider
CEO Director
Ian OConnell  Insider
CFO Director
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poolbeg Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Poolbeg Pharma Management Team Effectiveness

Poolbeg Pharma's management efficiency ratios could be used to measure how well Poolbeg Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Poolbeg Pharma Workforce Comparison

Poolbeg Pharma PLC is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 565. Poolbeg Pharma claims roughly 7.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.

Poolbeg Pharma PLC Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Poolbeg Pharma PLC Price Series Summation is a cross summation of Poolbeg Pharma price series and its benchmark/peer.

Poolbeg Pharma Notable Stakeholders

A Poolbeg Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Poolbeg Pharma often face trade-offs trying to please all of them. Poolbeg Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Poolbeg Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Poolbeg Pharma Management Performance

The success or failure of an entity such as Poolbeg Pharma PLC often depends on how effective the management is. Poolbeg Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Poolbeg management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Poolbeg management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Poolbeg Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 7 people.

Poolbeg Pharma Workforce Analysis

Traditionally, organizations such as Poolbeg Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Poolbeg Pharma within its industry.

Poolbeg Pharma Manpower Efficiency

Return on Poolbeg Pharma Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee444.3K
Net Loss Per Executive777.5K

Complementary Tools for Poolbeg Pink Sheet analysis

When running Poolbeg Pharma's price analysis, check to measure Poolbeg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poolbeg Pharma is operating at the current time. Most of Poolbeg Pharma's value examination focuses on studying past and present price action to predict the probability of Poolbeg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poolbeg Pharma's price. Additionally, you may evaluate how the addition of Poolbeg Pharma to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.